Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) Sees Large Decrease in Short Interest

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totaling 17,252 shares, a decline of 30.6% from the March 15th total of 24,866 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 43,602 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Drugs Made In America Acquisition

Institutional investors and hedge funds have recently made changes to their positions in the stock. Context Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter worth approximately $2,568,000. Clear Street Group Inc. bought a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter worth approximately $2,152,000. Wolverine Asset Management LLC raised its stake in shares of Drugs Made In America Acquisition by 22.2% during the 3rd quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock worth $12,829,000 after purchasing an additional 227,222 shares in the last quarter. Radcliffe Capital Management L.P. raised its stake in shares of Drugs Made In America Acquisition by 316.7% during the 3rd quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock worth $5,424,000 after purchasing an additional 401,378 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter worth approximately $1,024,000.

Drugs Made In America Acquisition Stock Performance

NASDAQ DMAA opened at $10.52 on Tuesday. The stock’s 50 day moving average price is $10.48 and its two-hundred day moving average price is $10.39. Drugs Made In America Acquisition has a 52 week low of $10.02 and a 52 week high of $10.52.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank?check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.